Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0
|
作者：
Smit, E. [1 ]
Ahn, M-J [2 ]
Dagogo-Jack, I. [3 ]
Felip, E. [4 ]
Gelsomino, F. [5 ]
Johnson, B. [6 ]
Johnson, M. [7 ]
Negrao, M. V. [8 ]
Offin, M. [9 ]
Ramalingam, S. [10 ]
Sanborn, R. [11 ]
Tsao, A. [8 ]
Wilner, K. [12 ]
Alcasid, A. [13 ]
Usari, T. [14 ]
Zhang, X. [15 ]
Riely, G. [9 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA
[12] Pfizer, La Jolla, CA USA
[13] Pfizer, Collegeville, PA USA
[14] Pfizer, Milan, Italy
[15] Pfizer, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
non-small cell lung cancer; encorafenib; binimetinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA06.13
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [21] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    ESMO OPEN, 2021, 6 (06)
  • [22] TRIDENTE trial: A phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type/BRAF V600E-mutant metastatic colorectal cancer.
    Kotani, Daisuke
    Kagawa, Yoshinori
    Matsubara, Yuki
    Bando, Hideaki
    Harada, Kazuaki
    Takahashi, Naoki
    Mihara, Yoshiaki
    Nakayama, Izuma
    Izawa, Naoki
    Kawakami, Takeshi
    Masuishi, Toshiki
    Hasegawa, Hiroko
    Ohta, Takashi
    Wakabayashi, Masashi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS264 - TPS264
  • [23] Tumor biomarker analysis from COLUMBUS part 1: Encorafenib plus binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
    Dummer, R.
    Pathan, N.
    Deng, S.
    Robert, C.
    Fernandez, A. M. Arance
    de Groot, J. W. B.
    Garbe, C.
    Gogas, H. J.
    Gutzmer, R.
    Krajsova, I.
    Liszkay, G.
    Loquai, C.
    Mandala, M.
    Schadendorf, D.
    Yamazaki, N.
    di Pietro, A.
    Xie, T.
    Ascierto, P. A.
    Flaherty, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S902 - S902
  • [24] Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
    Tabernero, Josep
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Loupakis, Fotios
    Hong, Yong Sang
    Steeghs, Neeltje
    Guren, Tormod Kyrre
    Arkenau, Hendrik-Tobias
    Garcia-Alfonso, Pilar
    Elez, Elena
    Gollerkeri, Ashwin
    Maharry, Kati
    Christy-Bittel, Janna
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 273 - +
  • [25] A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)
    Kobayashi, S.
    Bando, H.
    Taketomi, A.
    Takamoto, T.
    Shinozaki, E.
    Shiozawa, M.
    Hara, H.
    Yamazaki, K.
    Komori, K.
    Matsuhashi, N.
    Kato, T.
    Kagawa, Y.
    Yokota, M.
    Oki, E.
    Takahashi, S.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S736 - S737
  • [26] STARBOARD: encorafenib plus binimetinib plus pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma
    Schadendorf, Dirk
    Dummer, Reinhard
    Robert, Caroline
    Ribas, Antoni
    Sullivan, Ryan J.
    Panella, Timothy
    McKean, Meredith
    Santos, Edgardo S.
    Brill, Kimberli
    Polli, Anna
    di Pietro, Alessandra
    Ascierto, Paolo A.
    FUTURE ONCOLOGY, 2022, 18 (17) : 2041 - 2051
  • [27] Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
    Augustyn, Kourtney
    Joseph, Jocelyn
    Patel, Anisha B.
    Razmandi, Azadeh
    Ali, Amatul Noor
    Tawbi, Hussein A.
    MELANOMA RESEARCH, 2023, 33 (05) : 406 - 416
  • [28] Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
    Moro, Kazuki
    Saiki, Takuro
    Sasaki, Kenta
    Matsumoto, Akio
    Zhou, Qiliang
    Nakano, Mae
    Nakano, Masato
    Matsumoto, Yoshifumi
    Shimada, Yoshifumi
    Moriyama, Masato
    Wakai, Toshifumi
    Saijo, Yasuo
    ANNALS OF ONCOLOGY, 2022, 33 : S541 - S541
  • [29] TREATMENT EXPERIENCE WITH ENCORAFENIB PLUS BINIMETINIB FOR BRAF V600-MUTANT METASTATIC MELANOMA: MANAGEMENT INSIGHTS FOR CLINICAL PRACTICE
    Holbrook, Kourtney
    Tawbi, Hussein
    Joseph, Jocelyn
    Patel, Anisha
    Razmandi, Azadeh
    Noor, Amatul
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [30] COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB plus BINIMETINIB
    Hahn, E.
    Rashid, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S19 - S19
12345